First European Conference on SRS/SBRT and IG-IMRT Held in Milan

Mon Mar 4, 2013 2:30am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130304:nPn3035776


SUNNYVALE, California,  March 4, 2013  /PRNewswire/ --

Accuray Incorporated (Nasdaq: ARAY), today announced highlights from the First
European Conference on stereotactic radiosurgery/stereotactic body radiation
therapy (SRS/SBRT) and image-guided intensity-modulated radiation therapy
(IG-IMRT), hosted in partnership with the Istituto Europeo di Oncologia Milano
and the Università degli studi  di Milano, held in  Milan, Italy  on  February
22-23, 2013.

The conference "Radiation Oncology: can we still treat without image guidance?"
was attended by more than 400 healthcare professionals, including radiation
oncologists, medical physicists and hospital administrators from 32 countries.
Outcomes of recent research in areas such as central nervous system (CNS), head
and neck, breast, lung, gastrointestinal (GI), pelvis, total marrow irradiation
(TMI) and pediatrics were presented.

The independent Scientific Committee, led by Prof.  Roberto Orecchia  (Istituto
Europeo di Oncologia  Milano, Italy) and Prof.  Eric Lartigau  (Centre Oscar
Lambret,  Lille, France), focused on new developments in the field and developed
an educational event to discuss the need of image guidance for a variety of
clinical indications in modern radiation therapy. "Daily image guidance is
crucial for all high-precision treatments, also for palliative treatments" said
Prof.  Eric Lartigau.

"The TomoTherapy System provides an automatic process that makes our daily work
easy" said Prof.  Dirk Verellen, UZ Brussel.

Prof.  Ben Heijmen, Erasmus MC-Daniel den Hoed Cancer Center of  Rotterdam, said
"Additionally, dose to the healthy tissue can be strongly reduced using optimal
and numerous non-coplanar beams when treating prostate cancer" comparing
non-coplanar treatments to coplanar treatments.

"There are non-adaptive and real-time adaptive solutions, but the only solution
that adapts for target motion in real-time, available clinically, is the
CyberKnife System", added Dr.  Iciar Santa Olalla.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that
develops, manufactures and sells personalized, innovative treatment solutions
that set the standard of care with the aim of helping patients live longer,
better lives. The Company's leading-edge technologies deliver the full range of
radiation therapy and radiosurgery treatments.

Safe Harbor Statement  Statements made in this press release that are not
statements of historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release relate, but are not
limited, to clinical applications, clinical results, patient outcomes, and the
Company's leadership position in radiation oncology innovation. Forward-looking
statements are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including risks detailed from
time to time under the heading "Risk Factors" in the company's report on Form
10-K filed on  September 10, 2012, as updated in our Form 10-Qs filed on 
November 8, 2012  &  February 6, 2013, and as updated periodically by our other
filings. Forward-looking statements speak only as of the date the statements are
made and are based on information available to the Company at the time those
statements are made and/or management's good faith belief as of that time with
respect to future events. The Company assumes no obligation to update
forward-looking statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking information,
except to the extent required by applicable securities laws.  Accordingly,
investors should not place undue reliance on any forward-looking statements.

Contacts

Anja Kleber

Marketing Director

Tél +33(0)1-55-23-20-20
akleber@accuray.com


Sophie Baumont
Edelman Paris

Tél +33(0)1-56-69-75-94
sophie.baumont@edelman.com


SOURCE  Accuray Incorporated

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.